Assessment of Treatment Safety and Quality of Life in Patients Receiving Etanercept Biosimilar for Autoimmune Arthritis

CompletedOBSERVATIONAL
Enrollment

583

Participants

Timeline

Start Date

April 4, 2014

Primary Completion Date

March 19, 2018

Study Completion Date

March 19, 2018

Conditions
Rheumatoid ArthritisAnkylosing SpondylitisPsoriatic Arthritis
Interventions
DRUG

Etanercept

Patients received biosimilar etanercept 25 mg twice weekly or 50 mg once weekly.

Trial Locations (10)

Unknown

Connective Diseases Research Center, Tabriz University of Medical Sciences, Tabriz

Hafez Hospital, Shiraz

Razi Hospital, Rasht

Ghaem Hospital, Mashhad

Golestan Hospital, Ahvāz

Alzahra Hospital, Isfahan

Personal Office, Isfahan

Kerman University of Medical Sciences, Kerman

Personal Office, Shiraz

Rheumatology Research Center, Tehran University of Medical Sciences, Tehran

Sponsors
All Listed Sponsors
lead

AryoGen Pharmed Co.

INDUSTRY